Emoxibel - instructions for use, dose, side effects, contraindications

Composition:Per 1 liter: active substance: methyl ethylpyridinol hydrochloride (emoxypine) 30 g; Excipients: sodium sulfite, sodium hydrogen phosphate dodecahydrate, water for injection.

Description:Transparent colorless or slightly colored liquid.

Pharmacotherapeutic group:Antioxidant.

ATX: & nbsp

S.01.X.A Other drugs for the treatment of eye diseases

Pharmacodynamics:It is an inhibitor of free radical processes, an antihypoxant and an antioxidant. Reduces blood viscosity and platelet aggregation, increases the content of cyclic nucleotides (cAMP and cGMP) in platelets and brain tissue, has fibrinolytic activity, reduces the permeability of the vascular wall and the risk of developing hemorrhages, contributes to their resorption. Expands coronary vessels, in the acute period of myocardial infarction limits the magnitude of the focus of necrosis, improves the contractility of the heart and the function of its conductive system. At the raised arterial pressure (BP) has an antihypertensive effect.In acute ischemic impairment of cerebral circulation reduces the severity of neurologic symptoms, increases tissue resistance to hypoxia and ischemia.

Pharmacokinetics:When administered intravenously at a dose of 10 mg / kg, the elimination half-life is 0.3 hours; total clearance CL - 0.2 l / min; the apparent volume of distribution is 5.2 liters. The drug quickly penetrates into the organs and tissues, where it is deposited and metabolized. Metabolites of methyl ethyl pyridinol, represented by dealkylated and conjugated products of its transformation, were detected. Methylethylpyridinol metabolites are excreted by the kidneys. In significant quantities, 2-ethyl-6-methyl-3-hydroxypyridine phosphate is found in the liver. With ischemic heart disease, bioavailability increases.

Indications:In the combination therapy:
- In neurology and neurosurgery: hemorrhagic stroke in the recovery period, ischemic stroke in the pool of the internal carotid artery and in the vertebrobasillar system, transient cerebral blood flow disorders, chronic cerebral circulatory insufficiency, craniocerebral trauma; postoperative period in patients with craniocerebral trauma,Operated for epi-, subdural and intracerebral hematomas, combined with bruises of the brain.
- In cardiology: acute myocardial infarction, prevention of "reperfusion" syndrome, unstable angina.

Contraindications:Hypersensitivity, pregnancy, lactation, children's age.

Carefully:Patients with hemostasis disorder, during surgical operations or patients with symptoms of severe bleeding (due to the effect on platelet aggregation).

Dosing and Administration:Intravenous or intramuscular.
The dose, the duration of the course of treatment is determined individually. For intravenous administration, the preparation is previously diluted in 200 ml of a 0.9% solution of sodium chloride or a 5% solution of dextrose.
In neurology and neurosurgery: intravenously drip at a rate of 20-30 cap per minute at a dose of 10 mg / kg / day for 10-12 days, then switch to intramuscular injection of 60-300 mg 2-3 times a day for 20 days.
In cardiology: intravenously drip at a rate of 20-40 cap per minute in a dose of 600-900 mg 1-3 times a day for 5-15 days, followed by a transition to intramuscular injection of 60-300 mg 2-3 times a day for 10-30 days .

Side effects:With intravenous administration, there may be a burning sensation and pain along the veins; may be an increase in blood pressure, agitation or drowsiness, a violation of blood clotting. In rare cases, headache, pain in the heart, nausea, discomfort in the epigastric region, itching and redness of the skin are possible.

Overdose:Symptoms: increased side effects of the drug (the emergence of drowsiness and sedation), a short-term increase in blood pressure.
Treatment: symptomatic, incl. the appointment of antihypertensive drugs under the control of blood pressure. There is no specific antidote.

Interaction:Methyl ethylpyridinol is pharmaceutically incompatible with other medicinal products, therefore mixing in one syringe or infusionum with other injecting agents is not allowed.

Special instructions:Treatment with Emoxibel, in the case of its intravenous and intramuscular injection, should be carried out under the control of blood pressure and the functional state of the coagulating and anticoagulating blood systems.

Effect on the ability to drive transp. cf. and fur:Persons who report drowsiness or lowering blood pressure after using Emoxibel should refrain from driving and potentially dangerous mechanisms.

Form release / dosage:Solution for intravenous and intramuscular injection 30 mg / ml.

Packaging:5 ml per ampoule. 5 ampoules are placed in a contour mesh box made of a polyvinylchloride film and aluminum foil.
1 or 2 contour mesh packages together with the instruction for use and the ampoule scarifier are placed in a pack of cardboard.
When using ampoules with a break ring, it is allowed to pack the ampoules without an ampoule scarifier.
10 ml in bottles. Each bottle, together with the instructions for use, is placed in a pack of cardboard.
Packing for hospitals: 40 bottles with an equal number of instructions for medical use in carton boxes.

Storage conditions:In the dark place at a temperature of no higher than 25 ° C.
Keep out of the reach of children.

Shelf life:3 years.
Do not use after the expiration date.

Terms of leave from pharmacies:On prescription

Registration number:LSR-005101/10

Date of registration:01.06.2010 / 26.05.2015

Expiration Date:Unlimited

The owner of the registration certificate:BELMEDPREPARATY, RUP BELMEDPREPARATY, RUP Republic of Belarus

Manufacturer: & nbsp

BELMEDPREPARATY, RUP Republic of Belarus

Information update date: & nbsp2016-08-27

Illustrated instructions

Instructions

Emoxibel (Emoxibel)